Results 61 to 70 of about 21,836 (300)
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Cells, 2023 Candidiasis is a highly pervasive infection posing major health risks, especially for immunocompromised populations. Pathogenic Candida species have evolved intrinsic and acquired resistance to a variety of antifungal medications.
Karolina M. Czajka +8 more
doaj +1 more source
Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris [PDF]
, 2019 The enigmatic yeast Candida auris has emerged over the last decade and rapidly penetrated our consciousness. The global threat from this multidrug-resistant yeast has generated a call to arms from within the medical mycology community.
Kean, Ryan, Ramage, Gordon
core +2 more sources
Frontiers in PharmacologyEchinocandins, a prominent class of antifungals, are known for their broad-spectrum activity and favorable safety profiles. However, their bioavailability and efficacy via oral route are suboptimal. In this study, caspofungin and micafungin, the two most
Sepideh Mehravar +5 more
doaj +1 more source
Journal of Fungi, 2023 Candida parapsilosis is the second most common Candida species isolated in Asia, Southern Europe, and Latin America and is often involved in invasive infections that seriously impact human health. This pathogen is part of the psilosis complex, which also
Joana Branco +2 more
doaj +1 more source
Epidemiology of Echinocandin Resistance in Candida [PDF]
Current Fungal Infection Reports, 2014 Echinocandins are the newest antifungal agents approved for use in treating Candida infections in the US. They act by interfering with 1,3-β-D-glucan synthase and therefore disrupt cell wall production and lead to Candida cell death. There is no intrinsic resistance to echinocandins among Candida species, and isolates from historic collections archived
Shawn R. Lockhart +2 more
openaire +3 more sources
Microbiology SpectrumThe minimum inhibitory concentration (MIC) of echinocandins against Aspergillus spp. does not represent the actual inhibition threshold of echinocandins.
Assaf Potruch +5 more
doaj +1 more source
Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Journal of Fungi, 2018 Candida glabrata has thoroughly adapted to successfully colonize human mucosal membranes and survive in vivo pressures. prior to and during antifungal treatment. Out of all the medically relevant Candida species, C.
K. Healey, D. Perlin
semanticscholar +1 more source
Can Intravenous Antifungal therapy be safely used in the Outpatient Parenteral Antimicrobial Therapy (OPAT) setting? [PDF]
, 2019 Outpatient parenteral antimicrobial therapy (OPAT) is an established treatment option for patients with a variety of infections who require a period of intravenous therapy, are clinically stable, and do not require continuous monitoring.
Kenny, Claire +2 more
core +2 more sources
Successful management of recalcitrant fungal keratitis with topical caspofungin
GMS Ophthalmology Cases, 2022 Objective: To report a case of recalcitrant fungal keratitis successfully managed with topical caspofungin acetate in North India.Methods: Case report and literature review.Results: An 18-year-old male patient presented with complaints of redness ...
Goel, Siddhi +2 more
doaj +1 more source
Variability in antifungal and antiviral use in hospitalized children [PDF]
, 2017 We analyzed antifungal and antiviral prescribing among high-risk children across freestanding children’s hospitals. Antifungal and antiviral days of therapy varied across hospitals.
Gerber, Jeffrey S +6 more
core +2 more sources